FORMULATION, OPTIMIZATION AND IN VITRO CHARACTERIZATION OF LETROZOLE LOADED SOLID LIPID NANOPARTICLES
Abstract
Letrozole (LTZ) is an oral non-steroidal aromatase inhibitor for the treatment of hormonally responsive breast cancer after surgery. The objective of the current study is to prepare and evaluate Solid lipid nanoparticles (SLN) of LTZ. SLNs were prepared by hot homogenization followed by ultrasonication. Trimyristin was used as solid lipid core, Soyphosphatidyl choline, Tween 80 as surfactant mixture. Process and formulation variables were studied and optimized. LTZ-SLN were characterized for mean particle size, polydispersity index (PDI) and zeta potential for all the formulations. The mean particles size, PDI, zeta potential and entrapment efficiency of optimized LTZ-SLN optimized formulation was found to be 28.54 nm, 0.162, 11.80 mV, 85.64 %, respectively. In vitro release profiles are performed in 0.1N HCl using modified franz diffusion cell showed controlled drug release behavior over a period of 24h. LTZ-SLN formulations are subjected to stability study over a period of 1 month in terms of particle size, zeta potential, PDI, entrapment efficiency and are found to be stable. Differential scanning calorimetry (DSC) and transmission electron microscopy (TEM) analysis was performed to characterize the state of drug, lipid modification, shape and surface morphology of prepared LTZ-SLN formulations.
Keywords:
Letrozole, Solid lipid Nanoparticles, Trimyristin, stability, DSC, TEMDOI
https://doi.org/10.25004/IJPSDR.2014.060302References
2. Dingler A, Gohla S. Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J Microencapsul. 2002; 19:11-16.
3. Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev. 2001; 47:165-174.
4. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 2002; 242:121-129.
5. Shahgaldian P, Silva ED, Coleman AW, Rather B, Zaworotko MJ. Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int. J. Pharm. 2003; 253:23-32.
6. Suresh G, Manjunath, K, Venkateswarlu V, Satyanarayana V. Preparation, Characterization, and In Vitro and In Vivo Evaluation of Lovastatin Solid Lipid Nanoparticles. AAPS PharmSciTech. 2007; 8(1): E162–E170.
7. Yang SC., Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Contr Rel. 1999; 59:299-307.
8. Xiang Li, Shu-fang Nie, Jun Kongb, Ning Li, Cheng-yi Ju, Wei-san Pan. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int. J. Pharm. 2008; 363:177-182.
9. Zara GP, Cavalli R, Fundaro A, Bargoni A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharm Res. 1999; 40:281-286.
10. Yi Fan Luo, DaWei Chen, LiXiang Ren, XiuLi Zhao, Jing Qin. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Contr Rel. 2006; 114: 53-59.
11. Hong Yuan, Jing Miao, Yong-Zhong Du, Jian You, Fu-Qiang Hu, Su Zeng. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 2008; 348:137-145.
12. Jores, K, Mehenert W, Mader K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: A nuclear magnetic resonance study 2003; 20(8):1274-1283.
13. Schubert MA, Muller-Goymann CC. Solvent injection as a new approach for manufacturing lipid Nanoparticles-Evaluation of the method and process parameters. Eur. J. Pharm Biopharm. 2003; 55(1):125-131.
14. Catherine Charcosset, Assma El-Harati, Hatem Fessi. Preparation of solid lipid nanoparticles using a membrane contactor. J. Contr. Rel. 2005; 108:112-120.
15. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Contr. Rel. 2004; 95:627-638.
16. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Contr Rel. 2005; 107:215-228.
17. Cavalli R., Caputo O, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur. J. Pharm. Sci. 2000; 10:305-309.
18. Heurtault B, Saulnier P, Pech B. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003; 24:4283-4300.
19. Westesen K, Bunjes H. Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int. J. Pharm. 1995; 115:129-131.
20. Jenning V, Thünemann AF, Gohla, SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 2000; 199:167-177.
Published
Abstract Display: 380 
PDF Downloads: 491 
